Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | NOS1 | P29475 | 5/20 | 0.69 |
| ▸ | NOS3 | P29474 | 4/20 | 0.69 |
| ▸ | NOS2 | P35228 | 4/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL22347074 | 1.00 | BLM (1.00) | BLMCYP2D6CYP2C19KDM4ENPSR1 | |
| Sulfuric Acid SCHEMBL317855 | 1.00 | BLM (1.00) | BLMCYP2D6CYP2C19KDM4ENPSR1 | |
| Sulfuric Acid SCHEMBL29483831 | 0.97 | BLM (0.94) | BLMCYP2D6CYP2C19KDM4ENPSR1 | |
| Sulfuric Acid SCHEMBL4106019 | 0.86 | CYP2D6 (0.75) | BLMCYP2D6CYP2C19KDM4ENPSR1 | |
| SCHEMBL27962429 | 0.84 | KDM4E (0.71) | BLMCYP2D6CYP2C19KDM4ENPSR1 | |
| SCHEMBL78077 | 0.83 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL30740657 | 0.82 | KDM4E (0.68) | BLMCYP2D6CYP2C19KDM4ENPSR1 | |
| Urea SCHEMBL27606252 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL4633139 | 0.79 | — | — | |
| Iodide SCHEMBL916721 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1825 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606455-B2 | Preparation method of tungsten-doped cobalt tetraoxide and use thereof | GUANGDONG BRUNP RECYCLING TECHNOLOGY CO., LTD. (CN) | 2026-04-21 | — | — | US | claimed |
| CN-119855815-A | KRAS mutant protein inhibitor, and preparation method and application thereof | 甘李药业股份有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119707834-A | Preparation method of arbeli and intermediate thereof | 常州制药厂有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119462497-A | Pyridopyrimidinone Process for the preparation of compounds | 上海皓元医药股份有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119351583-A | Method for quantifying microbial activity of sediment influenced by antibiotics with high resolution | 自然资源部第三海洋研究所 | 2025-01-24 | — | — | CN | claimed |
| CN-113203851-B | ELisa method for detecting carbendazim and kit thereof | 北京奥本生物技术有限公司 | 2024-10-22 | — | — | CN | claimed |
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-09-26 | — | — | US | claimed |
| CN-118538492-A | Manufacturing process of radio-frequency high-power through hole type diamond resistor | 厦门大学 | 2024-08-23 | — | — | CN | claimed |
| CN-118307446-A | Preparation method of 1- (7-amino heptyl) guanidine sulfate | 北方民族大学 | 2024-07-09 | — | — | CN | claimed |
| CN-117926354-A | Pulse cyanide-free gold electroplating liquid and electroplating method thereof | 深圳市联合蓝海应用材料科技股份有限公司 | 2024-04-26 | — | — | CN | claimed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | claimed |
| EP-1978997-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | Apollo Life Sciences Limited (AU) | 2008-10-15 | — | — | EP | claimed |
| US-20070243132-A1 | Transdermal delivery of pharmaceutical agents | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-10-18 | — | — | US | claimed |
| WO-2007070983-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-06-28 | — | — | WO | claimed |
| US-20040220242-A1 | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | claimed |
| US-20040220113-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | claimed |
| CN-1326785-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2001-12-19 | — | — | CN | claimed |
| US-6326513-B1 | Process for producing creatine or creatine-monohydrate | TIANJIN TIANCHENG PHARMACEUTICAL CO., LTD (CN) | 2001-12-04 | — | — | US | claimed |
| EP-0031109-B1 | GUANIDINIUM COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MICROBICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-05-11 | — | — | EP | claimed |
| EP-0071919-A2 | Spiro(benzofuran-2(3H),4'(2'H)-isoquinoline)s, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-02-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606455-B2 | Preparation method of tungsten-doped cobalt tetraoxide and use thereof | CA2, CA3, HCN4 | BLM 2121/4885CYP2D6 4351/4885CYP2C19 3643/4885 |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | BLM 4382/4885CYP2D6 1209/4885CYP2C19 1451/4885 |
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, SMN1; SMN2 | BLM 3073/4885CYP2D6 1154/4885CYP2C19 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.